Market Update (NYSE:LLY): Lilly’s Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes

[PR Newswire] – INDIANAPOLIS, Sept. 4, 2014 /PRNewswire/ — Eli Lilly and Company’s (LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus®) at 26 . . . → Read More: Market Update (NYSE:LLY): Lilly’s Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes Similar Articles: Market Update (NYSE:LLY): New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies Stock Update (NYSE:LLY): FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection) Market Update: Eli Lilly & Company (NYSE:LLY) – Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults